Quadrant Capital Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Quadrant Capital Group’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.98K	Hold	80	–	–	﹤0.01%	2508
2025 Q4	$1.87K	Hold	80	–	–	﹤0.01%	2533
2025 Q3	$1.58K	Buy	+80	New	+$1.65K	﹤0.01%	2511
2025 Q2	–	Sell	-842	Closed	-$20.4K	–	1619
2025 Q1	$20.4K	Buy	+842	New	+$19K	﹤0.01%	2025
2023 Q2	–	Sell	-81	Closed	-$1.34K	–	2705
2023 Q1	$1.34K	Buy	81 +16	+25%	+$264	﹤0.01%	2496
2022 Q4	$1.21K	Buy	+65	New	+$1K	﹤0.01%	2508

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Quadrant Capital Group's CPRX Position: Q1 2026 in Review

Quadrant Capital Group held its Catalyst Pharmaceutical (CPRX) position steady in Q1 2026 at 80 shares worth $1.98K. The position accounts for ﹤0.01% of the portfolio, ranked #2508.

Quadrant Capital Group first reported a position in CPRX in Q4 2022 and has held it in 6 quarters since. The position peaked at $20.4K in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Quadrant Capital Group held 80 shares of Catalyst Pharmaceutical worth $1.98K as of Q1 2026.
Quadrant Capital Group left its Catalyst Pharmaceutical share count unchanged in Q1 2026.
Catalyst Pharmaceutical made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2508 holding.
Quadrant Capital Group first reported a position in Catalyst Pharmaceutical in Q4 2022 and has held it in 6 quarters since.
Quadrant Capital Group's Catalyst Pharmaceutical position peaked at $20.4K in Q1 2025.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.